Pharmacetical Newswire

Pharmaceutical News!

Press release distribution service
Pharmaceutical Links

Pharmanewswire.Com: Pharmaceutical News

Pain Management Market Consumption Forecast by Application, Trends, Growth Rate and Key Companies

 



(PharmaNewsWire.Com, December 15, 2017 ) This report provides an in-depth insight of Global Pain Management Market covering all important parameters including development trends, challenges, opportunities, key manufacturers and competitive analysis.

Rescheduling of Hydrocodone combinations from Class III to Class II, clear-cut regulatory guideline for Abuse Deterrent drug formulation NDA & ANDA (solid oral) filing and CDC guideline for Prescribing Opioids for Chronic Pain (2016) are definite steps taken by FDA in last two years for creating “Abuse Deterrent Era” in a short span to stop opioid abuse and reversing opioid epidemic in USA. There were around 18,893deaths involving prescription of opioids in the United States in 2014 which was up 16% from 2013 as per NCHS (National Center for Health Statistics).

US Opioids market is of $8b in size and of which extended release formulations contribute 50%. ADF ER formulations and its generic versions & New NCEs targeting Opioid receptor will drive the growth of opioid market in US and Europe in coming years.

Get Sample Copy of Report@ http://www.reportsweb.com/inquiry&RW00020667/sample

In this report, we have discussed a number of novel delivery technologies employed in the formulating abuse deterrent product, technologies employed in enhancing patient compliances, emerging novel mechanisms and late stage pipeline drugs in the management of pain.

Late stage NCE pipeline drugs (Cebranopadol, Mirogabalin, NKT-181, AVP-923,…) and Novel technologies targeting formulation change in old generic drugs (ORB-201, OX-51, ARX-04,CL-108, once daily Pregabalin..) for pain management has potential to reduce opioids use in future to treat pain. While TRKA receptor antagonist, NAV1.7 sodium channel modulator inhibitor and angiotension II antagonist are few new MoA which has promising drug in clinical development for moderate to severe pain management.

Around +6 plus extended release abuse deterrent formulations with Abuse deterrent (AD) labels are approved in last two years (Xtampza ER, MorphaBond ER, Hysingla ER, Embeda ER, Targiniq ER, Oxaydo) and are expected to provide improvements over existing formulations for abuse deterrent purpose. But they have some limitation for restricting abuse mainly through oral intake- swallowing a number of intact tablets or capsules. Despite, Extended release (ER) Abuse Deterrent Formulations partly control Opioids abuse (through nasal or injection routes), ER opioids has high potential of abuse, its AD formulation add significant value to create “Abuse Deterrent Era” in the coming time.

Inquiry for This Report@ http://www.reportsweb.com/inquiry&RW00020667/buying

Around 20 plus Abuse Deterrent Formulations of opioids are in the pipeline and most of them are ER formulations which use different AD tech platform to make its ADF. Amongst these pipeline ADF drugs, 6 are of Hydrocodone, 8 are of Morphine and 6 are of Oxycodone based ADF formulations.

New NCEs targeting Opioids receptor are in pipeline which reduces Opioids abuse by its MoA (slow rate of entry in Brain) and may have potential to deal with reducing opioid abuse through restricting oral intake in coming years.

Companies mentioned:
-AbbVie
-AcelRx pharma
-Acorda Therapeutics
-Actavis
-Acura Pharma
-Acorda Therapeutics
-Altus formulations
-Alkermes
-Algiax Pharmaceuticals
-Amorsa Therapeutics
-AnGes
-AstraZeneca
-Balerna
-Biogen
-BioDelivery Sciences International Inc
-Biopharma
-Cara Therapeutics
-Catalent
-Charleston
-Celltech
-Collegium Pharma
-Convergence
-Columbia Labs
-Convatech
-Daiichi Sankyo
-Daewoong
-Depomed
-Durect
-Egalet
-Eli Lilly
-Elite Pharma
-Endo

Get Discount@ http://www.reportsweb.com/inquiry&RW00020667/discount

-Ensyce Bioscience
-EpiCept
-Flamel Technologies
-Flexion Therapeutics
-Forest
-Glenmark
-Grunenthal
-GlaxoSmithKline
-GW Pharma
-Immune Pharmaceuticals
-Impax Pharmaceuticals
-Inspirion
-Intelli Pharmaceutics
-IRX Therapeutics
-Johnson and Johnson
-KemPharm
-Kineta
-Kunwha Pharmaceutical
-Medallion Therapeutics
-Mallinckrodt
-Nektar
-Novartis
-Noven
-Orbis Biosciences
-Orexo
-Otsuka
-Pain Therapeutics
-Pfizer
-ProPharma
-Purdue
-Recro pharma
-Relmada Therapeutics
-Reckitt Benckiser pharmaceutical
-Signature Therapeutics
-Spinifex pharma
-SPR Therapeutics
-Strativa
-Teikoku
-Teva
-Tesa Labtec GmpH
-Trevena Inc
-Tris Pharma
-Valeant
-ViroMed
-Wooddiff Lake
-Xenon Pharma
-XenoPort

Buy This Report@ http://www.reportsweb.com/buy&RW00020667/buy/3500

Table Of Content:
1. Executive Summary
2. Management of Pain
3. FDA Schedule for controlled substances and advantage of Schedule III over II
4. FDA Perspective on Abuse deterrent formulations (Opioids)
5. Approved Abuse deterrent Formulations by FDA - Development , label claim, Technology and current prescription trend
6. Abuse Deterrent Technology Platforms employed in marketed drugs and pipeline
7. Pipeline analysis of Novel Technologies and new mechanisms in Pain management
Novel Technologies
New mechanisms in Pain management
8. Late stage pipeline developments in neuropathic pain
Appendix – I FDA Guidelines for the development of abuse Deterrent Formulations
Appendix- II General Principles for Evaluating the Abuse deterrent Generic Solid Oral Opioid Drug Products



ReportsWeb.com

Rajat Sahni

+1-646-491-9876

sales@reportsweb.com

Source: EmailWire.Com

Source: EmailWire.com


Pharmaceutical Sponsors

Free Biotech & Pharmaceutical Magazines

Pharmacy Newswire Video Feed

Pharmaceutical & Biotech Resources
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:

IronPort Provides Email Management and Analysis for a Premier Health Care Solutions Provider
Pharmaceutical & Medical Packaging News
Medical Laboratory Observer

No credit cards, coupons, or promo codes required. Try it today!

Pharmanewswire.com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © GroupWeb Media LLC. All Rights Reserved.

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com, or contact us.
Copyright 2009 GroupWeb Media LLC
GroupWeb Media Network

Aviation-NewsWire | ArtNewsWire | Auction NewsWire | CRM NewsWire | ePhotoNewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | i-Homeland Security.Com | iMac-NewsWire.Com | i-Press-Release-Service | i-SoftwareNews.com | iT-NewsWire.Com
| i-TravelNewsWire.Com | MoneyNewsWire.Net | Movie-Stars-News.Com | MSNewsWire.Net | PharmaNewsWire.Com | Publishing-NewsWire.Com | RSSNewsWire.Net | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com | VoIPNewsWire.Net | XSportsWorld.Net
Pharmanewswire.com - Pharmaceutical Newswire and Press Release service of GroupWeb Media LLC